In June 2011, Poniard announced a definitive merger agreement with Allozyne, Inc., a privately held biotechnology company focused on bioconjugated protein therapeutics, which would combine Allozyne's autoimmune disease product pipeline with Poniard's oncology assets. The combined company was expected to focus on advancing Allozyne products and seek a partnership for continued development of picoplatin. The company's current operational status and pipeline progress are unclear based on available public data.
Cyborg Score Rationale
The company traded on NASDAQ as recently as mid-2011 but has since migrated to OTC penny-stock status with a market cap near zero. Clinical trial data is from the 2007-2009 period. No recent operational milestones or financial disclosures are evident.
Top Insights
Company transitioned from NASDAQ to OTC penny-stock trading, indicating substantial shareholder dilution or delisting
Lead program (Picoplatin Phase III) underwent clinical development through ~2009 but no recent advancement reported
2011 merger with Allozyne was strategically intended to redirect toward autoimmune platform, but execution/outcomes unclear
Minimal recent financial or operational disclosure suggests company may be dormant, abandoned, or in wind-down status
Recent Developments
(June 2011) Definitive merger agreement signed with Allozyne, Inc. to combine oncology and autoimmune pipelines
(June 2011) Announced intent to seek partnership for continued development of picoplatin
(2007) Completed $70 million financing and initiated Phase 3 trial of Picoplatin in small cell lung cancer
Open the full interactive Poniard Pharmaceuticals, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.